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In recent years, a diverse array of in vitro cell-derived models of
mammalian development have been described that hold immense
potential for exploring fundamental questions in developmental
biology, particularly in the case of the human embryo where
ethical and technical limitations restrict research. These models
open up new avenues toward biomedical advances in in vitro fertilization, clinical research, and drug screening with potential to
impact wider society across many diverse fields. These technologies raise challenging questions with profound ethical, regulatory,
and social implications that deserve due consideration. Here, we
discuss the potential impacts of embryo-like models, and their
biomedical potential and current limitations.

The emergence of in vitro embryo-like models of mammalian development represents a remarkable advance in the
field of developmental biology (see this issue) and ushers
in a set of powerful new tools to complement the repertoire
of model organisms such as mouse and non-human primates that have served as a reference for human biology
over the last 50 years. Research with non-human mammalian embryos is challenging because of their intrauterine
development which offers limited access to experimental
material, as well as concerns driving the principles of reduction, refinement, and replacement for use of animals in
research (the ‘‘3Rs’’ principles). Embryo-like models, often
based on pluripotent stem cells (PSCs), create an opportunity for affordable examination of various fundamental
principles of development in a high-throughput, accessible, and experimentally tractable manner within the
3Rs regulatory framework. In addition, such systems often
utilize ‘‘bottom-up’’ bioengineering approaches that seek
to deconstruct the complexity of the embryo by focusing
on specific stages of development, tissues, or cell types,
with the overall aim to provide additional and complementary insights into the guiding principles and core molecular
and functional components of embryonic development
(Fu et al., 2021; Heemskerk, 2020; Tewary et al., 2018)
While mouse cell-based in vitro systems have proved
crucial to establishing the background and feasibility of
embryo-like models, the greatest benefits of such systems
are likely to be found in the study of human development.
Historically, this field has relied on the availability of material from collections of human embryos, including the one

gathered under the umbrella of the Carnegie Institution
(Noe, 2004; O’Rahilly and Müller, 1987), which provide a
major resource for the study of human embryology. However, the transformation of descriptive embryology into
causal developmental biology in the second half of the
20th century, alongside associated advances in cell and molecular biology, raise the need for an experimental analysis
of human development. While it remains possible to
obtain early human embryos with consent and within
ethical frameworks, these embryos are limited in availability and do not provide a wide scope for mechanistic studies
of development. Research leading to in vitro fertilization
(IVF) in the 1970s and 1980s (Steptoe et al., 1971) opened
up the possibility of growing human embryos in culture
and this, in turn, led to discussions of the ethical limits of
such experiments. The result was the day-14 rule that acts
as a widely accepted temporal limit for research with IVFderived human embryos, and uses gastrulation and the formation of the primitive streak as a discrete, albeit somewhat arbitrary, cutoff aimed to prevent the acquisition of
‘‘individualization’’ in culture (Warnock, 1984, 1985).
Despite early expectations, the growth of fertilized human eggs in vitro beyond pre-implantation stages has
proved challenging. However, inspired by work with
mouse embryos, new methods have been reported to
enable the culture of human and non-human primate embryos in the laboratory up or even beyond the 14th day (Deglincerti et al., 2016a; Shahbazi et al., 2016; Xiang et al.,
2020). The success rates of these experiments are still low,
and routine practice of such approaches is still limited by
the ‘‘special status’’ of human embryos (Jones, 2011), for
which some have argued that a 3Rs principle should also
apply, similar to that used in animal research (Bioethics,
2017). Notwithstanding these issues, recent experiments
and emerging observations highlighting differences between mouse and human embryos (Ghimire et al., 2021)
have raised the need to modify the day-14 rule to be able
to explore human development at peri-gastrulation stages
(Hurlbut et al., 2017; Hyun et al., 2016). In the meantime,
the search for appropriate models to study this period of
development has led to an increased use of closely related
species, in particular non-human primates. However, the
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Figure 1. Schematic summary of the potential applications, benefits, and limitations of in vitro embryo models compared with
embryos for research and therapy

cost of these experiments as well as ethical issues associated
with individual jurisdictions make this research difficult. It
is in the face of these challenges that recent progress with
human PSC-based embryo-like models has led to their
emergence as powerful alternatives to the use of embryos.
Recent technological advances that utilize human PSCs
to create embryo-like models of trilineage germ layer emergence (Deglincerti et al., 2016b; Warmflash et al., 2014),
peri-implantation stage epiblast (Simunovic et al., 2019),
post-implantation amniotic sac embryoids (PASEs) (Shao
et al., 2017b) (Shao et al., 2017a; Zheng et al., 2019), and
axially organized post-implantation-like structures (Marikawa et al., 2020; Moris et al., 2020) provide a new suite
of powerful tools that researchers can use to study human
development without the need to use actual human
1022 Stem Cell Reports j Vol. 16 j 1021–1030 j May 11, 2021

embryos. Despite their obvious potential, such technologies also raise a number of serious concerns, which need
to be dealt with at the outset. It is therefore imperative
that we critically assess and appreciate the implications of
these techniques early on so as to initiate wide discussion
cognizant of the many opportunities presented as well as
the ongoing and expected future challenges and questions
raised. To foster this discussion, we provide here a view of
the overall potential, the scientific and technological limitations, and possible ethical and societal issues raised by
embryo-like model systems (Figure 1).
Biomedical applications
Model systems focusing on the recapitulation and analysis
of early human embryonic development have an obvious

Stem Cell Reports
Perspective

potential when applied to the field of reproductive biology,
in particular fertility research and pregnancy loss, whereby
experiments with these models might lead to improvements in assisted reproduction technologies (ART). In addition, since exposure to certain substances and medications
during the early stages of embryonic development can
have detrimental effects on the organization of the embryo, affecting the development of specific organs and tissues, there is potential to examine the effect of perturbations on normal developmental processes. Studying these
effects is the realm of toxicology and teratology, and embryo-like models are likely to provide a valuable tool to
assess the effects of such environmental and epigenetic
stressors on the development of the human embryo.
Also, there has been a great expansion in our knowledge
of human developmental disorders during the past 5 years,
including identification of the genetic basis of disease.
Further exploration of the mechanisms by which genotype
can be linked to phenotype could make use of model systems in which genetic manipulation is experimentally tractable and could also make use of the advent of induced
pluripotent stem cells (iPSCs) to develop patient-relevant
models. Additional applications might include the derivation of cell types or tissue samples which could be applied
to further research (particularly for rare cell types that
require multiple tissue inputs during development) or
used toward cell therapy in the clinic.
Each of these fields represents an exciting new opportunity for embryo-like models to contribute beyond basic
research and toward biomedical applications. However,
there are also limitations and further considerations that
are required of these models, which we discuss here in
more detail.
Reproductive research
Only an estimated 30% of human conceptions will lead to
a live birth (Zinaman et al., 1996), with the underlying
mechanistic cause for such a low figure still being unclear.
Most are associated with failures during the first 6 weeks
of development, with an estimated 50% of these being
traced to the pre-implantation stage of development.
Reproductive failures are thought to be due to a variety of
reasons, including gamete abnormalities that limit fertilization, karyotypic disorders, immunological dysregulation, and defects in the process of implantation (Fleming
et al., 2018; Jarvis, 2016; Larsen et al., 2013). As such, demand for ART procedures has been steadily increasing
over the past few decades, and an estimated 7 million babies have been born using these technologies since 1978
(Adamson et al., 2018a). However, despite these numbers,
the frequency of successful pregnancies derived from ART
still remains relatively low, e.g., 25%–30% for IVF and
around 50% for other techniques such as zygote and
frozen-embryo intrafallopian transfer. These figures have

fueled research into potential causes of such failures, with
a growing interest in novel ways to improve the culture
and successful development of zygotes generated in vitro.
Advances in techniques such as IVF (Casper et al., 2017)
that require culture of fertilized eggs in vitro, have provided
researchers with the ability to observe a critical period of
early pre-implantation human development (Gerri et al.,
2020). Observation of these early stages of human development has revealed unexpected features of early human
embryogenesis such as a high frequency of genetic mosaicism and chromosomal abnormalities (Ambartsumyan
and Clark, 2008; van Echten-Arends et al., 2011), speciesspecific signaling requirements (Kuijk et al., 2012; Roode
et al., 2012), human-specific transcription factor network
organization (Fogarty et al., 2017), and the ability to use
early morphological features to predict successful outcomes of blastocyst-formation (Wong et al., 2010). These
studies use surplus embryos from IVF and can suffer from
low numbers of available embryos as well as the difficulty
of following them through implantation. These problems
could possibly be circumvented with the establishment
and use of PSC-based models of pre-implantation development. Such systems exist in mouse, where in vitro aggregation of embryonic stem cells (ESCs) and trophoblast stem
cells (TSCs) under well-defined culture conditions leads to
the formation of structures—blastoids—resembling the
pre-implantation conceptus (Rivron et al., 2018b). The discovery of human TSCs has opened up the possibility of
creating similar structures for human cells, i.e., humanized
blastoids, which, when perfected, could be useful tools in
the study of defects in early pregnancy arising from problems in the interaction between embryonic and extraembryonic tissues. Such techniques using murine cells are
already beginning to reveal the role of communication between embryonic and extraembryonic tissues in the early
mouse embryo and further highlight the requirement of
signaling modulation in defined culture conditions suitable for pre-implantation development (Harrison et al.,
2017; Rivron et al., 2018b; Sozen et al., 2018). The establishment of naive human ESCs, capable of giving rise to
embryonic and all extraembryonic lineages, trophectoderm, and primitive endoderm, will likely further accelerate the development and analysis of human and non-human embryo-like model systems capable of reconstituting
at least some aspects of pre- and peri-implantation development (Guo et al., 2020; Linneberg-Agerholm et al., 2019;
Okae et al., 2018).
Each of the three initial lineages (epiblast, trophectoderm, and primitive endoderm) are specified during cleavage and blastocyst development and contribute to the
establishment of an embryonic-maternal interface necessary for further development and maturation of the embryo proper. Effective in vitro systems that can mimic and
Stem Cell Reports j Vol. 16 j 1021–1030 j May 11, 2021 1023
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reconstitute implantation in humans are still missing,
although some minor progress is being made with the
use of artificial matrices (Xiang et al., 2020). The development of microfluidic-controlled conceptus-like structures
is another important recent development in this emerging
arena of research (Zheng et al., 2019). These and other
similar tools, despite their lack of extraembryonic tissues,
allow the interrogation of peri-gastrulation stage embryonic development and are thus ideally placed to enable
large-scale screens and high-powered studies into this
period of human development. The recent establishment
of placental organoids (Turco et al., 2018) will likely
further enhance peri- and post-implantation development
research. In vitro embryo and placental models could
conceivably be assembled and combined into more
advanced models of implantation and peri-gastrulation
human development.
In light of recent advances, it is probable that future
studies will enable the identification of chemical cocktails
promoting the efficient development of early embryos under IVF conditions, while also identifying new tools and parameters able to predict successful early embryo development and implantation. It may even be possible to derive
methods that could be used to correct early defects during
embryogenesis, which would be a major addition to the
current suite of available ART tools. With increasing demand for reproductive technologies alongside an ongoing
debate about the use of human embryos in research, in vitro
embryo models could thus provide a solution and
contribute to rapid advances in reproductive biology
research while limiting the consumption of precious embryonic material. These tools could further contribute to
the development of novel infertility treatments, improvement of existing IVF technologies, and the design of novel
contraceptives.
Teratogenicity, drug discovery, and screening
While some early miscarriages can be correlated with lifestyle choices such as smoking, alcohol, diet, and maternal
age (Nybo Andersen et al., 2000), others can be caused by
exposure to drugs or medicines with secondary teratogenic
effects and to chemicals present in foods, drinks, and the
environment. A particularly well-documented study of
such an effect is the case of thalidomide, a 1950s non-barbiturate sedative that came to be prescribed as a remedy for
morning sickness. The compound had been deemed to be
safe after studies in mice showed no adverse effects in
this organism. However, in 1961 two clinicians, Widukind
Lenz and William McBride, reported a large number of abnormalities in fetuses and newborns that had been exposed
to thalidomide in utero. A well-publicized effect of thalidomide was phocomelia, a shortening and deformation of the
limbs, although the substance had a very wide range of effects (Vargesson, 2015). This devastating case highlighted
1024 Stem Cell Reports j Vol. 16 j 1021–1030 j May 11, 2021

the need to use non-mouse models for developmental
screening and suggested that some compounds might
have potentially human-specific susceptibility during
development. By 1962 thalidomide had been withdrawn
from the market worldwide and the consequences of its
use triggered new systematic studies of the effects of chemicals on embryo development, driving advances in the
fields of toxicology and teratology.
A central lesson from the thalidomide case was the need
to find appropriate tests for suspect compounds, often
known as DART (development and reproductive toxicology) tests. A wide range of studies suggests that compound exposure during peri-gastrulation stages of development is critical for the emerging phenotype of the
organism as, during this time, the principal germ layers
and from them the primordia of all organs and tissues
emerge and become organized in time and space. Having
identified the critical stage, the target is to identify an
experimental model system that can provide information
about the effects of various compounds within this developmental window. Mice, rabbits, and other non-rodent
mammals have for a long time provided a standard reference for toxicological studies in human development and
disease but, as well as species-specific differences in mechanisms and overall organization of the embryos, the lowthroughput nature of such studies and push toward 3Rs
principles limits their suitability at early stages of drug-discovery pipelines.
PSCs, including ESCs and iPSCs, open up the possibility
of doing screens and tests with high throughput on human-derived cells. Two systems have proved popular in
this context. In one of them PSCs are differentiated in
adherent (two-dimensional [2D]) culture and exposed to
defined substances of interest, and their possible phenotypic effects recorded to assess changes in gene or protein
expression at the end of the assay. While informative, these
cultures are only differentiated to a single lineage at a time,
and they lack the three-dimensional (3D) organization of
the cells in an embryo. To circumvent these problems,
embryoid bodies (EBs) (Brickman and Serup, 2017) have
become a workhorse of toxicology and teratology research.
However, both systems have problems when compared
with an embryo. The most obvious limitation is that while
both cases allow the directed differentiation of PSCs into
specific cell types and thus provide a substrate to test the effects of certain compounds, the cells are not in the relative
proportions and arrangements characteristic of embryos
and, in the case of EBs, the timing of the differentiation
bears little relationship to that of embryos. Furthermore,
in many instances a compound will affect the growth,
morphogenesis, and relative proportions of specific tissues
and organs in a specific manner in vivo, something that
cannot be mimicked by these simplistic PSC-based models,
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adherent 2D cultures, or disorganized EBs. Overall, these
existing simplistic 2D and 3D model systems are not
adequately suited for testing the diverse and potentially
harmful effects of compounds on human embryonic
development.
While there is a possibility of growing embryos in vitro
until or beyond gastrulation for such studies, the numbers
of embryos required for such experiments are often too
high to be feasible in a screening context (only about
20% of blastocysts in Xiang et al., 2020). Embryo-like
models, which can be established easily and in large quantities, represent potentially useful alternatives for these
high-throughput experimental requirements, and have
already begun to show promise toward this end.
Micropatterns, also called 2D-gastruloids, are arrays of
PSCs growing on printed adhesive substrates of defined
size and shape whose geometry triggers the processes of
self-organization characteristic of early development
(Warmflash et al., 2014). These structures have been
shown to recapitulate the organization of the principal
germ layers in a vertebrate embryo and can be used to
study the interactions between signaling and transcriptional networks. In particular, their flat morphology facilitates easy imaging, and their regular shape enables
computational averaging of replicates to provide
quantitative and robust measurements for screening. Human PSC-derived micropatterns have already been used
for teratogenicity assays and were able to reveal dosedependent responses to species-specific compounds
including thalidomide (Xing et al., 2015).
For compounds likely to affect earlier development, blastoids and PASEs probably make better models, since they
capture pre-gastrulation events. Similarly, gastruloids, 3D
aggregates of PSCs that recapitulate many of the events
associated with gastrulation, emergence of the body plan,
and axial extension (Fu et al., 2021; Veenvliet and Herrmann, 2020), might be able to provide an assay for later
stages and, in contrast to micropatterned culture, allow
assessment of development in three dimensions. Embryonal carcinoma cell-based gastruloids have already been
shown to be a useful tool to the study of toxicology (Warkus and Marikawa, 2017), but the development of gastruloids from human PSCs is also likely to provide a potential
assay (Marikawa et al., 2020; Moris et al., 2020). These
studies, promising as they are, could be limited by our
lack of understanding of pharmacokinetics and maternalfetal interfaces, which remain to be fully explored.
Despite these considerations, embryo-like models are
likely to become valuable tools for screening assays, with
particular potential in the fields of teratogenicity and
drug discovery because of their potential ability to recapitulate human-specific features in a high-throughput
manner.

Disease modeling
The normal development of the embryo can fail because of
various pathological conditions that lead to birth defects,
and in some cases can even lead to the death of the embryo
or fetus. In 2018 in the United Kingdom these affected
almost 7,000 births, corresponding to 1 baby in 47 births
being diagnosed with a congenital abnormality (Public
Health England, 2020). Some of these cases result from defects in the maternal-fetal interface but many are associated
with specific mutations that affect the development of the
embryo, in particular during the establishment of the body
plan around the process of gastrulation (Ferrer-Vaquer and
Hadjantonakis, 2013). In addition, non-genetic causes
(including environmental exposure) can often lead to
developmental abnormalities. Most common among these
are cardiac and limb defects, problems of neural tube
closure (e.g., spina bifida), segmentation defects of the
vertebrae, as well as orofacial clefts, and defects of the digestive tract (e.g., bowel malformations such as gastroschisis)
and congenital diaphragmatic hernia. Understanding the
origin of these pathologies represents a significant step
toward their remedy. Historically, knowledge of these pathologies has been gained through clinical observations
of individuals at birth, and while some conditions are fairly
common or have familial patterns of heredity, many are
rare and our knowledge relies largely on small case studies
and anecdotal evidence generally lacking full etiology
(Feldkamp et al., 2017).
Our limited knowledge of the mechanisms associated
with human gastrulation and the challenges of obtaining
material for studying this pivotal process create a barrier
to our understanding and treatment of these conditions.
When there is a clear association of a mutation in a specific
gene with a syndrome, model organisms have been used as
surrogates for the disease; Drosophila (Ugur et al., 2016),
Caenorhabditis elegans (Markaki and Tavernarakis, 2020),
and zebrafish (Adamson et al., 2018b) have been successfully used for this purpose, especially when the disease is
associated with a specific molecular alteration. However,
the physiological and, importantly, developmental differences between species (such as the differences in the development and function of the extraembryonic membranes)
present a barrier to the modeling of developmental abnormalities. It is for these reasons that the mouse, closer phylogenetically and developmentally than other classical
model organisms such as zebrafish, chick, or frog, has
become the organism of choice for the modeling of human
diseases (Raess et al., 2016; Rosenthal and Brown, 2007).
Despite their relatedness, there are substantial differences
between mouse and humans, and, on several occasions,
the mouse model has failed to capture important features
of human disease, for example cystic fibrosis or Cornelia
de Lange syndrome (Lavelle et al., 2016). However, similar
Stem Cell Reports j Vol. 16 j 1021–1030 j May 11, 2021 1025
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to the case of toxicology studies, the emergence of PSCs,
and in particular iPSCs, has opened the door to modeling
human diseases and performing related drug screens using
human cellular systems (Grskovic et al., 2011).
Adherent cultures recapitulate normal embryonic specification and differentiation pathways and have also been
shown to recapitulate many aspects of disease phenotypes,
for example, insulin-producing b cells and diabetes or
dopamine-producing neurons and Parkinson’s disease. A
remarkable feature of these in vitro differentiation processes
is that they occur in the absence of morphogenesis, i.e.,
they suggest a decoupling of the genetic programs from
their organization in space. A surprising example of this
is the ability of paraxial mesoderm derived from PSCs to
reproduce the segmentation clock, thought to contribute
to the generation of somites and the vertebral column,
and to differentiate into somitic mesoderm without a
context of tissue organization (Diaz-Cuadros et al., 2020;
Matsuda et al., 2020). Such properties have been exploited
to begin to understand the contribution of oscillations in
gene expression to vertebral column pathologies such as
spondylocostal dysostosis by the introduction of specific
mutations into iPSCs and the use of iPSC lines from patients suffering from this disease (Matsuda et al., 2020).
These and related experiments open up the way for the
study of pathologies with an origin in the early embryo.
These studies, using adherent cultures and micropatterns,
have uncovered previously unseen phenotypes associated
with human diseases.
Such studies could be enhanced by the addition of a 3D
organization and relative positioning of tissues and organ
primordia as seen in early embryos, which are likely to
play a role in the development of these particular diseases
and related pathologies. This could encompass both 3D
embryo-like models as well as tissue- or organ-specific organoids. In both cases, models are able to reproduce the
cellular and tissue-level organization of in vitro-derived
cells in space and time and may therefore represent
more realistic disease models. For instance, the development of endodermal organoids is very advanced in this regard (Kechele and Wells, 2019) and provides examples of
the significance of cell interactions for the development
of specific organs (Koike et al., 2019). Further advances
with these and other multi-germ layer-derived organoids
will prove to be very useful in modeling a variety of
neonatal and congenital diseases (Aurora and Spence,
2016). Others have used in vitro embryo models to study
late-onset diseases, including the use of PSCs with allelic
series of CAG repeats associated with Huntington’s disease
(Haremaki et al., 2019). In terms of embryo-like models,
gastruloids can give rise to the primordia of most tissues
and organs (Beccari et al., 2018; van den Brink et al.,
2020; van den Brink et al., 2014) and might provide a use1026 Stem Cell Reports j Vol. 16 j 1021–1030 j May 11, 2021

ful tool for disease modeling. The recent development of
human gastruloids from human ESCs (Moris et al.,
2020) is encouraging in this regard. Especially in combination with patient-derived iPSCs and CRISPR/Cas9-based
genome-editing technology, such models are likely to provide novel and valuable insights into human development and disease.
Wider context: ethical aspects
The nature of in vitro embryo-like models, in particular
their relationship with embryos and their biomedical potential, make it critical that researchers are acutely cognizant of the wider social context and potential impacts of
their research. This includes not only ethical considerations but also the general social, political, and regulatory
context in which this research takes place. It furthermore
demands an acknowledgment of the obligation to engage
in an open discussion across fields to define and establish
the boundaries of such research. This is particularly true
in the case of the generation of human embryo-like model
systems, which, although at an early stage of development,
have the potential to raise questions about the nature of
the structures they represent (Hyun et al., 2020; Rivron
et al., 2018a). Such discussions should encompass the regulation surrounding new technologies and technical advances of embryo-like models themselves, as well as the applications of these techniques in the future. Importantly,
they should avoid misrepresentations and hype that can
lead to negative interpretations of the work (Huch et al.,
2017), as is the case in the United States where there is
lack of clarity around whether researchers can use federal
funds for research with human ESCs that leads to synthetic
embryo-like structures (Subbaraman, 2020).
The extent to which human embryo-like models exactly
mirror events in the in vivo embryo is an important question that remains to be conclusively answered. Early attempts have begun to try to address this question with
pre-implantation concepti (Blakeley et al., 2015), transcriptomic comparison of single-cell datasets from human embryonic material (Tyser et al., 2020), and using multi-species in vitro embryo models in comparison with model
organisms as a means to triangulate with human embryos
(Moris et al., 2020). These techniques raise a paradoxical
dilemma: embryo-like models should be as similar as
possible to human embryos in order to support their utility
as a research substitute, while remaining sufficiently
different to preserve distinctions that ethically permit
research. A major issue for this fledging field is therefore
to define the ethically acceptable limit of embryo-like
models themselves. This decision needs to be based on
sense rather than hype and should be informed by contributions from biologists, clinicians, ethicists, philosophers,
and, wherever possible, public opinion.
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Recent discussions of ethical guidelines by the International Society for Stem Cell Research (Hyun et al., 2020;
Taniguchi et al., 2019) have sought to clarify the regulatory
landscape of this discussion by establishing the boundaries
of definitions for conceptus and embryo. One key point is a
distinction between structures with ‘‘full organismal potential’’ and model systems that are unable to develop or
manifest into a full organism. Despite differences in the
definition of the term ‘‘embryo’’ across jurisdictions
(Hyun et al., 2020; Pera, 2017; Pera et al., 2015), it has
been argued that ethical distinctions should be based on
the organismal potential of the system rather than on a
simplistic distinction between in vivo human embryos
and in vitro embryo-like models. Currently described human embryo-like models appear to fall well within the
boundaries of this definition: PASEs and gastruloids are
limited to specific aspects of development and do not
develop beyond a specific temporal stage of embryogenesis. Many models also lack specific cell types that preclude
further development, such as a lack of extraembryonic cell
types that prevent implantation and would prevent successful uterine transfers. As such, no existing human embryo-like model has predicted full organismal potential,
so these models currently fall within the ethical limits of
existing guidelines. However, it is difficult to imagine
how a new technique in the future could be rigorously
assessed for ‘‘full organismal potential’’ without severely
compromising the very ethical boundary that the rule attempts to protect. Further research may well focus on adaptations to extend or improve these techniques to make
them more representative of their in vivo counterparts. In
particular, the very recent development of human blastoids
(Liu et al., 2021; Yu et al., 2021) will raise questions since,
even though mouse blastoids have been shown to lack
the ability to fully implant and develop, it is conceivable
that protocol optimizations could overcome these technical barriers and they might therefore adopt full organismal potential and the ability to implant. At this point
we would suggest that these structures should be subject
to the 14-day rule and that their consideration should
evolve with changes related to this rule.
Further complications could also arise in assessing the
ethical status of embryo-like structures because they do
not necessarily follow ‘‘canonical embryogenesis’’ (Aach
et al., 2017). The term ‘‘potential’’ also raises various ethical
questions around exactly what support might be included
to fulfill that potential. Even a naturally conceived embryo
cannot support life unless it implants into the uterus, so
would an in vitro-derived human blastoid-type model
satisfy the requirement for ‘‘full organismal potential’’
even if it was never implanted? Similarly, reprogramming
experiments with iPSCs have shown that theoretically
any cell has to potential to give rise to a ‘‘full organism.’’

Such definitions therefore require further clarification,
and concrete limits should be set to prevent misunderstandings as the field continues to move forward.
While the exact boundaries of ethical acceptability for
embryo-like models and their design have begun to receive
attention, there has been little consideration of the consequences of the likely subsequent application of these techniques to various clinical and commercial applications. It
seems to be generally accepted that research on human embryo-like models and in vitro structures should not be used
for the purposes of assisted human reproduction directly,
i.e., implantation and gestation of in vitro-derived embryos
(Hyun et al., 2020), but we should be cognizant of the theoretical potential for this approach in future. There are
various reasons for this limitation, including technical considerations and safety issues as well as the ethical ambiguity
surrounding direct human reproduction.
One major benefit to in vitro embryo models is that they
could reduce the number of human embryos required for
research, thus contributing toward a ‘‘human 3Rs’’
approach. If the wider community did indeed agree that
the number of human embryos used for research should
be minimized, in a similar way to those of non-human primate and mouse embryos (and this is not necessarily the
case, given the wide availability of human blastocysts, for
example), then human in vitro embryo models could represent an alternative option that might be less ethically
loaded. Wider public and ethical engagement on this point
might well be important for future discussions.
Overall, it is becoming clear that embryo-like model
systems represent a huge potential for applications
beyond basic research and toward a host of biomedical
applications. Their utility in providing experimentally
tractable, high-throughput, and human-specific developmental insights makes them amenable to many different
approaches, and their further advancement holds considerable promise for the future. Beyond the fields discussed
here, they also have the potential to play a role in developing specific cell types for research, regenerative medicine, and perhaps even therapy. But we must also be aware
that we, as scientists and developers of these systems, need
to remain vocal in disseminating the current limitations
and further considerations of such technology. Additionally, as a fledgling field, the community must consider
wider implications of embryo-like techniques within the
context of our social, political, and regulatory landscape
beyond the confines of the laboratory.
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